Dr. Gray has a combination of scientific and financial expertise that provides unique insights for board leadership. She has served on several public-company boards over the last 15 years including: TetraLogic, a publicly held clinical-stage biopharmaceutical company focused on oncology and infectious diseases, Dyax Corp., a rare disease company acquired by Shire; ACADIA Pharmaceuticals, focused on commercialization of CNS therapies; and Juniper Pharmaceuticals, a supplier of high-end fee-for-service pharmaceutical development and clinical trials, acquired by Catalent. She also currently sits on the board of Sarepta, a precision medicine company with assets in rare neuromuscular diseases, including gene therapy for Duchenne muscular dystrophy. Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes. Early in her career Dr. Gray was  a scientist focused on new drug development, and subsequently worked in equities research before becoming a senior analyst and portfolio manager.